UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 61

Sortiert nach

A positive allosteric modulator for the muscarinic receptor (M1 mAChR) improves pathology and cognitive deficits in female APPswe/PSEN1ΔE9 mice

British journal of pharmacology, 2022-04, Vol.179 (8), p.1769-1783

2022

Link zum Volltext

Verfügbarkeit prüfen

Editorial: Methods and application in cardiovascular and smooth muscle pharmacology: 2021

Frontiers in pharmacology, 2022-10, Vol.13, p.1049022-1049022

2022

Link zum Volltext

Verfügbarkeit prüfen

Early metabolic impairment as a contributor to neurodegenerative disease: Mechanisms and potential pharmacological intervention

Obesity (Silver Spring, Md.), 2022-05, Vol.30 (5), p.982-993

2022

Link zum Volltext

Verfügbarkeit prüfen

Stromatoxin‐sensitive, heteromultimeric Kv2.1/Kv9.3 channels contribute to myogenic control of cerebral arterial diameter

The Journal of physiology, 2010-11, Vol.588 (22), p.4519-4537

2010

Link zum Volltext

Verfügbarkeit prüfen

Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington's pathology in zQ175 mice

Molecular brain, 2019-04, Vol.12 (1), p.35-35, Article 35

2019

Link zum Volltext

Verfügbarkeit prüfen

Sexual dimorphism of G protein-coupled receptor signaling in the brain

Neural regeneration research, 2024-08, Vol.19 (8), p.1635-1636

2024

Link zum Volltext

Verfügbarkeit prüfen

A M1 muscarinic acetylcholine receptor-specific positive allosteric modulator VU0486846 reduces neurogliosis in female Alzheimer’s mice

Biomedicine & pharmacotherapy, 2024-04, Vol.173, p.116388-116388, Article 116388

2024

Link zum Volltext

Verfügbarkeit prüfen

Autophagy is increased following either pharmacological or genetic silencing of mGluR5 signaling in Alzheimer's disease mouse models

Molecular brain, 2018-04, Vol.11 (1), p.19-8, Article 19

2018

Link zum Volltext

Verfügbarkeit prüfen

Targeting mGluR group III for the treatment of neurodegenerative diseases

Biomedicine & pharmacotherapy, 2023-12, Vol.168, p.115733-115733, Article 115733

2023

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Huntington’s disease phenotype progression in male and female heterozygous FDNQ175 mice

Molecular brain, 2023-09, Vol.16 (1), p.1-67, Article 67

2023

Link zum Volltext

Verfügbarkeit prüfen

mGluR5 regulates REST/NRSF signaling through N-cadherin/β-catenin complex in Huntington’s disease

Molecular brain, 2020-08, Vol.13 (1), p.1-15, Article 118

2020

Link zum Volltext

Verfügbarkeit prüfen

Metabotropic Glutamate Receptor 5 Antagonism Reduces Pathology and Differentially Improves Symptoms in Male and Female Heterozygous zQ175 Huntington's Mice

Frontiers in molecular neuroscience, 2022-02, Vol.15, p.801757-801757

2022

Link zum Volltext

Verfügbarkeit prüfen

ROK and Arteriolar Myogenic Tone Generation: Molecular Evidence in Health and Disease

Frontiers in pharmacology, 2017-02, Vol.8, p.87-87

2017

Link zum Volltext

Verfügbarkeit prüfen

Editorial: Emerging insights in glutamate receptor signaling in psychiatric, neurodevelopmental, and neurodegenerative diseases

Frontiers in cell and developmental biology, 2024, Vol.12, p.1388514-1388514

2024

Link zum Volltext

Verfügbarkeit prüfen

Noncanonical Metabotropic Glutamate Receptor 5 Signaling in Alzheimer's Disease

Annual review of pharmacology and toxicology, 2022-01, Vol.62, p.235

2022

Link zum Volltext

Verfügbarkeit prüfen

Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases

Pharmacology & therapeutics (Oxford), 2022-11, Vol.239, p.108275-108275, Article 108275

2022

Link zum Volltext

Verfügbarkeit prüfen

Adipose tissue mitochondrial dysfunction and cardiometabolic diseases: On the search for novel molecular targets

Biochemical pharmacology, 2022-12, Vol.206, p.115337, Article 115337

2022

Link zum Volltext

Verfügbarkeit prüfen

VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease

The Journal of neuroscience, 2023-06, Vol.43 (23), p.4365-4377

2023

Link zum Volltext

Verfügbarkeit prüfen

Metabotropic Glutamate Receptor 2/3 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 Huntington Disease Mice

The Journal of pharmacology and experimental therapeutics, 2021-10, Vol.379 (1), p.74

2021

Link zum Volltext

Verfügbarkeit prüfen

The Role of Neuroglial Metabotropic Glutamate Receptors in Alzheimer's Disease

Current neuropharmacology, 2023-02, Vol.21 (2), p.273-283

2023

Link zum Volltext

Verfügbarkeit prüfen

PKC-mediated cerebral vasoconstriction: Role of myosin light chain phosphorylation versus actin cytoskeleton reorganization

Biochemical pharmacology, 2015-06, Vol.95 (4), p.263-278

2015

Link zum Volltext

Verfügbarkeit prüfen

Optineurin deletion disrupts metabotropic glutamate receptor 5-mediated regulation of ERK1/2, GSK3β/ZBTB16, mTOR/ULK1 signaling in autophagy

Biochemical pharmacology, 2021-03, Vol.185, p.114427, Article 114427

2021

Link zum Volltext

Verfügbarkeit prüfen

Structural determinants governing β-arrestin2 interaction with PDZ proteins and recruitment to CRFR1

Cellular signalling, 2019-11, Vol.63, p.109361, Article 109361

2019

Link zum Volltext

Verfügbarkeit prüfen

Amelioration of perivascular adipose inflammation reverses vascular dysfunction in a model of nonobese prediabetic metabolic challenge: potential role of antidiabetic drugs

Translational research : the journal of laboratory and clinical medicine, 2019-12, Vol.214, p.121-143

2019

Link zum Volltext

Verfügbarkeit prüfen

mGluR5 Contribution to Neuropathology in Alzheimer Mice Is Disease Stage-Dependent

ACS pharmacology & translational science, 2020-04, Vol.3 (2), p.334-344

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(58)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(61)

Sprache

Englisch
(61)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A positive allosteric modulator for the muscarinic receptor (M1 mAChR) improves pathology and cognitive deficits in female APPswe/PSEN1ΔE9 mice

Editorial: Methods and application in cardiovascular and smooth muscle pharmacology: 2021

Early metabolic impairment as a contributor to neurodegenerative disease: Mechanisms and potential pharmacological intervention

Stromatoxin‐sensitive, heteromultimeric Kv2.1/Kv9.3 channels contribute to myogenic control of cerebral arterial diameter

Modulation of mTOR and CREB pathways following mGluR5 blockade contribute to improved Huntington's pathology in zQ175 mice

Sexual dimorphism of G protein-coupled receptor signaling in the brain

A M1 muscarinic acetylcholine receptor-specific positive allosteric modulator VU0486846 reduces neurogliosis in female Alzheimer’s mice

Autophagy is increased following either pharmacological or genetic silencing of mGluR5 signaling in Alzheimer's disease mouse models

Targeting mGluR group III for the treatment of neurodegenerative diseases

Comparison of Huntington’s disease phenotype progression in male and female heterozygous FDNQ175 mice

mGluR5 regulates REST/NRSF signaling through N-cadherin/β-catenin complex in Huntington’s disease

Metabotropic Glutamate Receptor 5 Antagonism Reduces Pathology and Differentially Improves Symptoms in Male and Female Heterozygous zQ175 Huntington's Mice

ROK and Arteriolar Myogenic Tone Generation: Molecular Evidence in Health and Disease

Editorial: Emerging insights in glutamate receptor signaling in psychiatric, neurodevelopmental, and neurodegenerative diseases

Noncanonical Metabotropic Glutamate Receptor 5 Signaling in Alzheimer's Disease

Targeting mGluR2/3 for treatment of neurodegenerative and neuropsychiatric diseases

Adipose tissue mitochondrial dysfunction and cardiometabolic diseases: On the search for novel molecular targets

VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease

Metabotropic Glutamate Receptor 2/3 Activation Improves Motor Performance and Reduces Pathology in Heterozygous zQ175 Huntington Disease Mice

The Role of Neuroglial Metabotropic Glutamate Receptors in Alzheimer's Disease

PKC-mediated cerebral vasoconstriction: Role of myosin light chain phosphorylation versus actin cytoskeleton reorganization

Optineurin deletion disrupts metabotropic glutamate receptor 5-mediated regulation of ERK1/2, GSK3β/ZBTB16, mTOR/ULK1 signaling in autophagy

Structural determinants governing β-arrestin2 interaction with PDZ proteins and recruitment to CRFR1

Amelioration of perivascular adipose inflammation reverses vascular dysfunction in a model of nonobese prediabetic metabolic challenge: potential role of antidiabetic drugs

mGluR5 Contribution to Neuropathology in Alzheimer Mice Is Disease Stage-Dependent

Suchergebnisse filtern